Biotronik study shows benefits of new SFA treatment approaches

Biotronik has presented new clinical data at the 2018 Leipzig Interventional Course that highlights the benefits its technology offers in superficial femoral artery (SFA) therapy.

Data from multiple clinical studies have shown how Biotronik devices can deliver excellent outcomes even in challenging patient groups, while also supporting the concept of low metal burden therapies for SFA conditions.

In BIOLUX P-III, the world's second largest drug-coated balloon registry, 700 out of 882 patients were treated with Biotronik's Passeo-18 Lux balloon, resulting in a primary patency rate of 85.2 percent and freedom from target lesion revascularisation among 94 percent of patients.

Meanwhile, the BIOFLEX PEACE and BIOLUX 4EVER studies offered evidence that a reactive treatment approach can make it possible to reduce metal burden by only using the necessary stent length, while retaining the anti-proliferative effect that drug-coated balloons provide.

Dr Alexander Uhl, vice-president of marketing for Biotronik's vascular intervention division, said: "This exciting data supports our belief that the Response Adapted Combination Therapy approach allows physicians to adopt a flexible, evidence-based approach for treating the SFA with minimal vessel burden."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.